CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 53 enrolled
Drug / intervention
Detailed motor testing, including FoG, in PD subjectsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03647137
NCT03647137N/ACompleted

Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD

VA Office of Research and Development·observational·Posted Aug 27, 2018·Updated Jan 5, 2024

In Brief

An observational study evaluating Detailed motor testing, including FoG, in PD subjects for Parkinson's Disease. Completed, enrolled 53 participants across 1 site.

Detailed Summary

Early stage Parkinson disease (PD) is characterized by a 'honeymoon' phase in terms of responsiveness of motor symptoms, including gait, to dopaminergic pharmacotherapy. Advancing PD is associated with disabling axial motor complications, such as freezing of gait (FoG), with decreased or even refractory dopamine responsiveness in over 50% of patients. The management of dopamine resistant gait problems represents the most important unmet need in PD. This study will related detailed motor testing to brain PET imaging to see if certain molecules (or lack thereof) involved with neurologic transmission in the brain are involved with FoG.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 27, 2018
Enrollment StartJun 7, 2016
Primary CompletionMay 26, 2021
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.8 years ago

Interventions

Detailed motor testing, including FoG, in PD subjectsother

Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic "on" and "off" state.